Drug Profile


Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Florida
  • Developer Alzamend Neuro; University of South Florida
  • Class Alzheimer vaccines; Cell therapies; Immunotherapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 24 Oct 2017 Alzamend Neuro announces intention to submit an IND to the US FDA for Alzheimer's disease
  • 24 Oct 2017 Alzamend Neuro plans a clinical trial for Alzheimer's disease in USA
  • 30 Jan 2017 Alzamend Neuro in-licenses patent related to use of amyloid beta peptides from the University of South Florida
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top